The recent downturn in biotech has battered Massachusetts’ world-renowned sector, and the political climate has only made it ...

The main reason for the downturn in Moderna’s stock is a significant drop in the demand for its COVID-19 vaccine.

The biotech’s mRNA vaccines were lauded by the first Trump administration but now are caught up in government changes to ...

Shares of major vaccine makers Moderna and Pfizer held steady even as U.S. health secretary Robert F. Kennedy Jr. abruptly ...

The Food and Drug Administration (FDA) has approved Moderna’s next-generation mRNA COVID-19 vaccine mNexspike ®.

Moderna (NASDAQ: MRNA) stock represented the ticket to an investing win. The company brought its coronavirus vaccine from ...

The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna ...

The Trump administration has canceled $766 million awarded to Moderna to develop a vaccine against potential pandemic ...

Trump HHS ends nearly $1 billion in funding to Moderna for mRNA bird flu vaccines, citing safety concerns and lack of ...

From eligibility to dosage and future rollout, here’s what you need to know about the FDA’s latest vaccine approval.

Moderna Inc. gained US approval for a new Covid vaccine for a narrower group of people, in the latest sign that regulators ...